Trial · NCT02303821
Adverse events2,880
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 2,880
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 1 (20 mg/m^2) | 4 | 5 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 1 (20/27 mg/m^2) | 5 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 2 (20/27 mg/m^2) | 2 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 2 (20/36 mg/m^2) | 4 | 7 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 2 (20/45 mg/m^2 | 3 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 2 (20/56 mg/m^2) | 3 | 10 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 2: B-cell (20/56 mg/m^2) | 37 | 61 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 2: T-cell (20/56 mg/m^2) | 23 | 44 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 1 (20 mg/m^2) | 1 | 5 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 1 (20/27 mg/m^2) | 1 | 6 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 2 (20/27 mg/m^2) | 1 | 3 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 2 (20/36 mg/m^2) | 0 | 7 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 2 (20/45 mg/m^2 | 1 | 4 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 2 (20/56 mg/m^2) | 3 | 10 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Phase 2: B-cell (20/56 mg/m^2) | 17 | 61 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Phase 2: T-cell (20/56 mg/m^2) | 11 | 44 | |
| other | Leukopenia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 1 (20 mg/m^2) | 0 | 5 | |
| other | Leukopenia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 1 (20/27 mg/m^2) | 1 | 6 | |
| other | Leukopenia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 2 (20/27 mg/m^2) | 0 | 3 | |
| other | Leukopenia | Blood and lymphatic system disorders | Phase 1b: Dose Escalation 2 (20/36 mg/m^2) | 0 | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02303821/events